

Drug Shown To Be Effective In Treating Stroke

Poster presentation at International Stroke Conference offers promise to ischemic stroke victims

New York, NY, USA - February 23, 2009 – Remedy Pharmaceuticals, Inc. today announced that an important human study validating the use of the key ingredient in RP-1127 for treating stroke was revealed at the 2009 International Stroke Conference as a poster presentation.

The presentation titled “Possible Neuroprotective Effects of Sulfonylureas in Diabetic Patients with Acute Ischemic Stroke” concluded that diabetic patients with acute ischemic stroke treated with the active ingredient of RP-1127 and other drugs in its class, had better outcomes. After correcting for the known predictors of poor outcome, patients receiving these drugs were less likely to die and more likely to be discharged home or to rehabilitation. This data provides further evidence that sulfonylureas may be beneficial in patients with acute ischemic stroke.

Stroke is the third leading cause of death in America, surpassed only by heart disease and cancer, and is the primary cause of serious long-term disability in adults. There are 795,000 strokes in the U.S. each year, resulting in nearly 150,000 deaths. Annual costs to the healthcare system are estimated at \$56.8 billion.

Details of the poster follow:
International Stroke Conference Oral and Poster Presentations.
Stroke. 2009 Feb 16. P51.

About RP-1127

Remedy’s lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NC_{Ca-ATP} channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

About Remedy Pharmaceuticals

Remedy Pharmaceuticals, Inc. is a development stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: info@remedypharmaceuticals.com